109744-85-6

Basic information

• Product Name: 2-(2-methylphenyl)-benzimidazole
• Synonyms: 2-(2-methylphenyl)-benzimidazole
• CAS NO: 109744-85-6
• Molecular Formula: C₂₀H₁₆N₂
• Molecular Weight: 208.25848
• Mol File: 109744-85-6.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(2-methylphenyl)-benzimidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-methylphenyl)-benzimidazole(109744-85-6)
• EPA Substance Registry System: 2-(2-methylphenyl)-benzimidazole(109744-85-6)

Safety Data

• Hazardous Substances Data: 109744-85-6(Hazardous Substances Data)

Upstream product

• 118-90-1 ortho-methylbenzoic acid 
• 534-85-0 N-phenyl-1,2-benzenediamine 
• 933-88-0 ortho-toluoyl chloride 
• 529-20-4 2-methylphenyl aldehyde 
• 32622-24-5 N-phenyl-2-(2-methylphenyl)formamidine 
• 98-80-6 phenylboronic acid 

Relevant articles and documents

Benzimidazoles: A new class of carbonic anhydrase inhibitors

Carbonic anhydrase inhibitory activity of benzimidazole derivatives 1-24 has been evaluated. Compounds 22 (IC50 = 7.47 ± 0.39 μM), 21 (IC50 = 10.31 ± 0.11 μM), 20 (IC50 = 23.1 ± 1.78 μM), 12 (IC50 = 12.16 ± 0.10

Copper catalyzed N-arylation of amidines with aryl boronic acids and one-pot synthesis of benzimidazoles by a Chan-Lam-Evans N-arylation and C-H activation/C-N bond forming process

Mono-N-arylation of benzamidines 1 with aryl boronic acids 2 was effectively achieved in the presence of a catalytic amount of Cu(OAc) 2 and NaOPiv under mild aerobic conditions. Combining this step with an intramolecular direct C-H bond functionalization, catalyzed by the same catalytic system but under oxygen at 120 C, afforded benzimidazoles 3 in good to excellent yields.

Methods of treating or preventing interstitial cystitis

PCT No. PCT/US97/03895 Sec. 371 Date Aug. 25, 1998 Sec. 102(e) Date Aug. 25, 1998 PCT Filed Mar. 7, 1997 PCT Pub. No. WO97/33873 PCT Pub. Date Sep. 18, 1997This invention provides methods for the treatment or prevention of interstitial cystitis or urethral syndrome in a mammal which comprise administering to a mammal in need thereof an effective amount of a substituted benzimidazole, or a pharmaceutically acceptable salt or solvate thereof.